Reference SummaryAnisimov VN, Mech Ageing Dev 2001 Jan;122(1):41-68

Title

Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice.

Authors

Anisimov VN; Khavinson VK; Mikhalski AI; Yashin AI

Journal

Mech Ageing Dev

Volume

122

Issue

1

Year

2001

Pages

41-68

Abstract

Fifty female CBA mice were injected s.c. either with 0.1 ml saline, or with synthetic thymic dipeptide Lys-Glu or with synthetic pineal tetrapeptide Ala-Glu-Asp-Gly both in a single dose of 0.1 microg/animal monthly for five consecutive days from the age of 6 months until natural death. Lys-Glu did not significantly influence the body weight and food consumption, free radical processes and estrus function in mice and did increase their physical activity with the subsequent decrease in spontaneous lung adenomas incidence. The pineal peptide treatment was failed to modify the food consumption and physical strength of mice, and was followed by the increase in the body weight, mean survival (by 5.3%, P<0.05) and maximum (by 10 months), by slow down of the ageing of estrus function, by the decrease in body temperature, physical activity, free radical processes and spontaneous tumor incidence (mainly, lung adenomas) in mice. These data suggest the geroprotector potential of the pineal peptide.

Links

11163623 – National Library of Medicine/PubMed

Strain Notes

Strain Note
CBA/Rap Mice used in this experiment were purchased from "'Rappolovo' Animal Farm of the Russian Academy of Medical Sciences (St. Petersburg)".

Models

Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
CBA/Rap Blood vessel hemangioma Blood vessel

6.0

CBA/Rap Blood vessel hemangioma
  • peptide Lys-Glu
Blood vessel

2.0

CBA/Rap Blood vessel hemangioma
  • peptide Ala-Glu-Asp-Gly
Blood vessel

0

CBA/Rap Leukocyte lymphoma Leukocyte

0

CBA/Rap Leukocyte lymphoma
  • peptide Lys-Glu
Leukocyte

4.0

CBA/Rap Leukocyte lymphoma
  • peptide Ala-Glu-Asp-Gly
Leukocyte

4.0

CBA/Rap Lung adenocarcinoma Lung

0

CBA/Rap Lung adenocarcinoma
  • peptide Lys-Glu
Lung

2.0

CBA/Rap Lung adenocarcinoma
  • peptide Ala-Glu-Asp-Gly
Lung

2.0

CBA/Rap Lung adenoma Lung

20

CBA/Rap Lung adenoma
  • peptide Lys-Glu
Lung

10

CBA/Rap Lung adenoma
  • peptide Ala-Glu-Asp-Gly
Lung

4.0

CBA/Rap Mammary gland adenocarcinoma Mammary gland

6.0

CBA/Rap Mammary gland adenocarcinoma
  • peptide Lys-Glu
Mammary gland

2.0

CBA/Rap Mammary gland adenocarcinoma
  • peptide Ala-Glu-Asp-Gly
Mammary gland

10

CBA/Rap Mammary gland adenoma Mammary gland

2.0

CBA/Rap Mammary gland adenoma
  • peptide Lys-Glu
Mammary gland

0

CBA/Rap Mammary gland adenoma
  • peptide Ala-Glu-Asp-Gly
Mammary gland

0

CBA/Rap Muscle - Smooth leiomyosarcoma Uterus

0

CBA/Rap Muscle - Smooth leiomyosarcoma
  • peptide Lys-Glu
Uterus

0

CBA/Rap Muscle - Smooth leiomyosarcoma
  • peptide Ala-Glu-Asp-Gly
Uterus

2.0

CBA/Rap Skin papilloma Skin

0

CBA/Rap Skin papilloma
  • peptide Lys-Glu
Skin

2.0

CBA/Rap Skin papilloma
  • peptide Ala-Glu-Asp-Gly
Skin

0

CBA/Rap (Unspecified organ) tumor (Unspecified organ)

30

CBA/Rap (Unspecified organ) tumor
  • peptide Lys-Glu
(Unspecified organ)

20

CBA/Rap (Unspecified organ) tumor
  • peptide Ala-Glu-Asp-Gly
(Unspecified organ)

18